128 related articles for article (PubMed ID: 8641984)
1. Detection of low-level expression of P-glycoprotein in ACHN renal adenocarcinoma cells.
Kawamoto S; Deguchi T; Nezasa S; Yamada S; Okano M; Kawada Y
Jpn J Cancer Res; 1996 May; 87(5):475-9. PubMed ID: 8641984
[TBL] [Abstract][Full Text] [Related]
2. Correlation of expression levels of P-glycoprotein with resistance to adriamycin in a renal adenocarcinoma cell line.
Kawamoto S; Deguchi T; Nezesa S; Yamada S; Okano M; Kawada Y
Urol Res; 1997; 25(6):407-12. PubMed ID: 9443650
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42.
Moran E; Cleary I; Larkin AM; Amhlaoibh RN; Masterson A; Scheper RJ; Izquierdo MA; Center M; O'Sullivan F; Clynes M
Eur J Cancer; 1997 Apr; 33(4):652-60. PubMed ID: 9274450
[TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells.
Stein U; Walther W; Shoemaker RH
J Natl Cancer Inst; 1996 Oct; 88(19):1383-92. PubMed ID: 8827016
[TBL] [Abstract][Full Text] [Related]
5. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
6. The expression of mdr-1-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines.
Yu DS; Chang SY; Ma CP
Br J Urol; 1998 Oct; 82(4):544-7. PubMed ID: 9806185
[TBL] [Abstract][Full Text] [Related]
7. Molecular diagnosis of multidrug resistance.
Herzog CE; Bates SE
Cancer Treat Res; 1994; 73():129-47. PubMed ID: 7710903
[No Abstract] [Full Text] [Related]
8. Validation of a single point flow cytometric assay for determining P-glycoprotein activity in multidrug resistant cell lines.
Chin-Yee I; Crowther MA; Keeney M; Wright L; Daly S
Clin Lab Haematol; 1994 Sep; 16(3):261-72. PubMed ID: 7828413
[TBL] [Abstract][Full Text] [Related]
9. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
10. [Enhancement of cytotoxic effect of anticancer agents of renal cell carcinoma].
Okano M; Kawamoto S; Nezasa S; Tamaki M; Ehara H; Yamada S; Deguchi T; Kawada Y
Nihon Hinyokika Gakkai Zasshi; 1996 Aug; 87(8):1041-7. PubMed ID: 8831211
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of human multidrug resistance 1 (MDR1) gene expression by nonisotopic competitive reverse transcriptase polymerase chain reaction assay.
Kobayashi H; Takemura Y; Miyachi H; Kawabata M; Mori S; Kawai Y; Furihata K; Sekiguchi S; Watanabe K
J Clin Lab Anal; 1997; 11(5):258-66. PubMed ID: 9292393
[TBL] [Abstract][Full Text] [Related]
12. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).
Robey RW; Zhan Z; Piekarz RL; Kayastha GL; Fojo T; Bates SE
Clin Cancer Res; 2006 Mar; 12(5):1547-55. PubMed ID: 16533780
[TBL] [Abstract][Full Text] [Related]
13. Low-level doxorubicin resistance in P-glycoprotein-negative human pancreatic tumour PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion.
Verovski VN; Van den Berge DL; Delvaeye MM; Scheper RJ; De Neve WJ; Storme GA
Br J Cancer; 1996 Mar; 73(5):596-602. PubMed ID: 8605092
[TBL] [Abstract][Full Text] [Related]
14. Expression of the multidrug transporter, P-glycoprotein, in renal and transitional cell carcinomas.
Nishiyama K; Shirahama T; Yoshimura A; Sumizawa T; Furukawa T; Ichikawa-Haraguchi M; Akiyama S; Ohi Y
Cancer; 1993 Jun; 71(11):3611-9. PubMed ID: 8098269
[TBL] [Abstract][Full Text] [Related]
15. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein.
Broxterman HJ; Lankelma J; Pinedo HM
Eur J Cancer; 1996 Jun; 32A(6):1024-33. PubMed ID: 8763344
[No Abstract] [Full Text] [Related]
16. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells.
Meschini S; Calcabrini A; Monti E; Del Bufalo D; Stringaro A; Dolfini E; Arancia G
Int J Cancer; 2000 Sep; 87(5):615-28. PubMed ID: 10925353
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance-associated protein-mediated multidrug resistance modulated by cyclosporin A in a human bladder cancer cell line.
Kim WJ; Kakehi Y; Hirai M; Arao S; Hiai H; Fukumoto M; Yoshida O
Jpn J Cancer Res; 1995 Oct; 86(10):969-77. PubMed ID: 7493917
[TBL] [Abstract][Full Text] [Related]
18. New flow cytometric method for detection of minimally expressed multidrug resistance P-glycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED670 conjugate.
Takeshita A; Shinjo K; Ohnishi K; Ohno R
Jpn J Cancer Res; 1995 Jun; 86(6):607-15. PubMed ID: 7622426
[TBL] [Abstract][Full Text] [Related]
19. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.
Ludescher C; Hilbe W; Eisterer W; Preuss E; Huber C; Gotwald M; Hofmann J; Thaler J
J Natl Cancer Inst; 1993 Nov; 85(21):1751-8. PubMed ID: 8105101
[TBL] [Abstract][Full Text] [Related]
20. Cellular pharmacology of mitoxantrone in p-glycoprotein-positive and -negative human myeloid leukemic cell lines.
Consoli U; Van NT; Neamati N; Mahadevia R; Beran M; Zhao S; Andreeff M
Leukemia; 1997 Dec; 11(12):2066-74. PubMed ID: 9447822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
